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Background: Adult-onset Still’s disease (AOSD) is rare inflammatory disease of unknown etiology that usually
affects young adults. The more common clinical manifestations are spiking fevers, arthritis, evanescent rash,
elevated liver enzymes, lymphadenopathy, hepatosplenomegaly, and serositis. The multi-visceral involvement of
the disease and the different complications, such as macrophage activation syndrome, may strongly decrease the
life expectancy of AOSD patients.
Methods: This study aimed to identify the positive and negative features correlated with the outcome of patients.
A retrospective analysis of AOSD patients prospectively admitted to three rheumatologic centers was performed to
identify the clinical features present at the time of diagnosis and to predict the possible outcome. Furthermore, we
investigated the as yet to be validated prognostic value of the systemic score previously proposed.
Results: One hundred consecutive AOSD patients were enrolled. The mean systemic score showed that the
majority of patients had a multi-organ involvement. Sixteen patients showed different complications, mainly the
macrophage activation syndrome. A strong increase of inflammatory markers was observed. All patients received
steroids at different dosages, 55 patients in association with immunosuppressive drugs and 32 in association with
biologic agents. Sixteen patients died during the follow-up. Regression analysis showed that the higher values of
the systemic score and the presence of AOSD-related complications, assessed at the time of diagnosis, were
significantly correlated with patient mortality. A prognostic impact of the systemic score of ≥ 7.0 was reported.
Conclusions: Our study showed that a higher systemic score and the presence of AOSD-related complications
at the time of diagnosis were significantly associated with mortality. Of note, a cut-off at 7.0 of the systemic score
showed a strong prognostic impact in identifying patients at risk of AOSD-related death.
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Adult-onset Still’s disease (AOSD) is a rare, systemic, in-
flammatory disorder of unknown etiology with an esti-
mated incidence of 0.14–0.40 cases per 100,000 people
and a prevalence of 1–34 cases per million people [1, 2].
It affects young adults, with a higher prevalence in women
[2–4] and most commonly presents with high daily spiking
fever, arthritis and evanescent rash. Other clinical features
include sore throat, elevated liver enzymes, lymphadenop-
athy, hepatosplenomegaly, and serositis [5–7].
The diagnosis is often delayed because of the low spe-
cificity of most findings. However, the favorable effects
of an early diagnosis on prognosis have been underlined
[8]. Basically, three different clinical patterns of AOSD
have been identified: (1) monocyclic pattern, character-
ized by a systemic single episode; (2) polycyclic pattern,
characterized by multiple flares lasting for a 1 year or
longer, alternating with remissions; and (3) chronic pat-
tern, related to a persistently active disease with associated
polyarthritis [9]. Usually, 30% of AOSD patients develop a
monocyclic pattern, 30% a polycyclic pattern, and 40% a
chronic pattern [2]. The monocyclic and polycyclic pat-
terns have been considered as part of the systemic form of
AOSD. On the contrary, the persistently active disease
with associated chronic polyarthritis takes the articular
form, suggesting that the underlying immunological im-
balance might be different between these forms and could
partially explain the reported differences in effectiveness
of different therapeutic agents [10–13]. Moreover, AOSD
patients may experience several severe complications
associated with a decrease in life expectancy, such as
macrophage activation syndrome (MAS), thrombotic
thrombocytopenic purpura, respiratory distress syndrome,
and diffuse alveolar hemorrhage [14–21].
In patients with AOSD, laboratory tests reflect the
systemic inflammatory process and high levels of both
erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP). In addition, serum ferritin levels are much
higher than those observed in other autoimmune, inflam-
matory, infectious, or neoplastic diseases, characterized by
decreased glycosylated ferritin (<20%) [22, 23]. Depite the
poor specificity, a 5-fold increase of serum ferritin levels
are strongly suggestive of AOSD and, furthermore, it is
generally considered a useful marker to assess the activity
of the disease [24, 25].
The treatment of AOSD remains largely empirical,
lacking controlled clinical trials [26]. Systemic corticoste-
roids are usually the first line therapy when systemic symp-
toms predominate, and often in combination with synthetic
disease-modifying anti-rheumatic drugs (sDMARDs)
such as methotrexate (MTX) [26]. In the last years,
many biological agents, mainly interleukin (IL)-1 and
IL-6 inhibitors, have been successfully used in refractory
cases [10, 11].At present, only few studies have focused on the prog-
nostic factors of the disease [2, 4–6]. Moreover, most stud-
ies were single center studies based on a limited number
of patients. To overcome these limitations, we planned a
retrospective analysis of patients prospectively admitted to
three different rheumatologic centers. Our study clearly
identified the clinical features present at the time of diag-
nosis, predicting the possible different patient outcomes.
Furthermore, we investigated the thus far non-validated
prognostic value of the systemic score proposed by
Pouchot et al. in 1991 [27].
Methods
A total of 100 AOSD patients who fulfilled at least five
(two major criteria and three minor criteria) of the
Yamaguchi diagnostic criteria [28] and who were con-
secutively admitted to three rheumatologic centers from
January 1, 2000, to December 31, 2015 were enrolled.
The rheumatologic centers were selected by their expertise
on management of AOSD and in the inception cohort
studies. In this study, we could not use Fautrel’s criteria
for AOSD diagnosis because none of the healthcare facil-
ities associated with our university hospitals evaluates gly-
cosylated ferritin levels [1, 23]. Although the specificity of
Fautrel’s criteria is higher (98.5%), this datum is balanced
by the higher sensitivity of the used criteria (Yamaguchi’s
criteria sensitivity 96.2% vs. Fautrel’s criteria sensitivity
80.6%) [1, 23, 28].
The following clinical features at diagnosis were re-
corded: fever, typical rash, arthralgia or arthritis, myalgia,
lymphadenopathy, sore throat, splenomegaly, hepato-
megaly or abnormal liver function tests, abdominal pain,
sore throat, weight loss, and gastrointestinal symptoms.
Pleural effusion or pleuritis and lung parenchymal in-
volvement were evaluated by a chest radiograph or CT
scan, and pericarditis was evaluated by echocardiog-
raphy. Table 1 shows the main demographic findings of
our patients. The clinical workup before the AOSD
diagnosis considered the exclusion of potential mimickers
[1, 2]. We excluded infections by blood cultures and, in
MAS patients, bone marrow cultures, serology, PCR
analyses, chest X-rays, and abdominal echography. We
evaluated the possible differential diagnosis with malig-
nancies using chest X-rays, abdominal echography, and
blood samples. Despite these exams, in the case of fur-
ther suspicion, we added CT and/or PET/CT exams to
the diagnostic workup. With regards to patients with
possible hematologic cancers, we also performed bone
marrow examination and lymph node biopsy. Autoimmune
diseases were excluded by blood tests, antinuclear anti-
bodies, anti-citrullinated peptide autoantibodies, rheuma-
toid factor, and anti-neutrophil cytoplasmic antibodies,
and for the exclusion of systemic vasculitides we included
tissue biopsy and arteriography in the workup. Finally, we
Table 1 Demographic and clinical features of the enrolled
patients at the time of diagnosis
Clinical data Patients
Women/men 66/34
Age, years ± SD 45.35 ± 16.23
Systemic score, mean ± SD 6.11 ± 2.02
Comorbidities, number (%) 33 (33)
Outcome
Favorable outcome, number (%) 84 (84)
Monocyclic course 29 (29)
Polycyclic course 22 (22)
Chronic course 33 (33)
Unfavorable outcome, number (%) 16 (16)
AOSD-related death 16 (16)
Time of follow-up, years (mean ± SD) 3.53 ± 2.93
Median survival time (25%, 75%), years 2.5 (1.8–5)
Ruscitti et al. BMC Medicine  (2016) 14:194 Page 3 of 11evaluated a possible differential diagnosis with autoinflam-
matory diseases by the execution of gene analyses.
Each patient was assessed for the systemic score pro-
posed by Pouchot et al. [27] for AOSD. This score as-
signs 1 point to each of 12 manifestations: fever, typical
rash, pleuritis, pneumonia, pericarditis, hepatomegaly or
abnormal liver function tests, splenomegaly, lymphaden-
opathy, leukocytosis > 15,000/mm3, sore throat, myalgia,
and abdominal pain (maximum score: 12 points). It has
been used as a score for systemic disease [6, 27, 29], but
its predictive value has never been investigated thus far.
In addition, at the time of diagnosis, each patient was
characterized for the presence of AOSD-related compli-
cations such as MAS, thrombotic thrombocytopenic
purpura, thrombotic microangiopathy, disseminated
intravascular coagulopathy, respiratory distress syn-
drome, diffuse alveolar hemorrhage, pulmonary arterial
hypertension, myocarditis, tamponade, constrictive peri-
carditis, endocarditis, shock, multiple organ failure, ful-
minant hepatitis, and amyloidosis, as suggested by the
available literature [14]. MAS was defined following the
diagnostic criteria proposed by the Histiocyte Society in
1991 and updated in 2004 and by Fardet L. et al. [30–33].
In AOSD-related MAS patients, the prognostic factors
were assessed [34].
In our cohort, we investigated the presence of comor-
bidities at the time of diagnosis. Comorbidities were de-
fined as coexisting medical conditions distinct from the
principal diagnosis for which the patient was enrolled in
this study [35].
Treatment regimens used in the course of disease were
categorized into four groups, i.e., low/medium dose of
steroids: ≤ 0.5 mg/kg/day of prednisone; high dose of
steroids as > 0.5 mg/kg/day of prednisone; combinationtherapy with steroids plus sDMARD(s); and steroids plus
biologics agent with or without sDMARD(s).
According to the disease course, at the last scheduled
visit, patients were divided into four groups as described
by Cush et al. [9]: the three classic clinical patterns
(monocyclic, polycyclic, and chronic) and death, which-
ever the course. A monocyclic course was defined as a
single episode for more than 2 months but less than
1 year followed by sustained remission through the en-
tire follow-up period. A polycyclic course was character-
ized by recurrent systemic flares with remission between
flares. A chronic course was defined as at least one epi-
sode of persistent symptoms lasting longer than 1 year.
Expired patients were defined as those who were diagnosed
with AOSD and died during follow-up. AOSD-related
death was defined as death associated with AOSD or its
complications during the follow-up. Moreover, remission
was defined as the complete disappearance of systemic
symptoms and normalization of laboratory evidence of
disease activity for at least two consecutive months, re-
gardless of therapy. Flare was characterized by systemic
fares occurring after remission [9, 27]. In this study, we
considered the need of any additional treatments and/or
any increased dosages of drugs as a flare of the disease.
The correlations between any disease feature and outcome
were investigated.
The local ethics committee (Azienda Sanitaria Locale
1 Avezzano/Sulmona/L’Aquila, L’Aquila, Italy; protocol
number 0139815/16) approved the procedure, which
was performed according to the Good Clinical Practice
guidelines and to the Declaration of Helsinki.
Statistical analysis
An observational prospective design was set in order to
provide a risk model profile for AOSD patients. Due to
the relatively simple design and the expertise of the
recruiting centers, we did not have missing data that
could impair our analyses. The statistical analysis pro-
vided preliminary descriptive statistics both for supposed
predictors and for the AOSD-dependent variable assumed
as response. An exploratory χ2 analysis and exploratory lo-
gistic univariate analysis were carried out to clarify the
possible associations and provide indications to select can-
didate predictors. The correlation between complications
and the other selected clinical variables has been estimated
using a point biserial correlation with the corresponding
P values. An ordered logistic risk model, adjusted by
sex and age, was performed to provide odds ratio estima-
tions for the independent variables previously selected.
The assumed latent linear behavior of the response
variable underwent a Brandt test (P < 0.05). The overall
model fitting was estimated using a likelihood ratio test
(LR = 91.55, P < 0.0001), using the empty one as a reference
model. According to the inferential analysis performed in
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chotomized: dead versus alive patients, patients with mono-
cyclic pattern versus other, patients with polycyclic pattern
versus other, patients with chronic pattern versus other.
This strategy allowed the study, exploiting logistic regres-
sions, of the significant predictors detected in the general
ordinal logistic model. Due to the low number of AOSD-
related complications, at the time of diagnosis, we did not
perform any statistical analysis for single complications.
Thus, we decided to aggregate these covariates into a single
dichotomous variable.
The analysis suggested a reasonable clinical application
of the systemic score as predictor of the disease condition
upshot. The analysis dealt with this issue categorizing the
AOSD outcome variable into a dichotomous variable,
which divided patients into dead or alive. A statistical as-
sociation between AOSD death and the systemic score
was preliminarily assessed (χ2 (df = 10) = 23.32; P = 0.01).
Then, a receiver operating characteristic (ROC) validation
analysis was carried out, obtaining an overall performance
of the test in terms of the area under the ROC curve
(AUC = 0.80 ± 0.06). The test sensitivity and specificity
was estimated according to the Youden criteria, obtaining
a systemic score cut-off of 7.0. The last step tested the
consistency of this cut-off in discriminating the survival
of those having systemic score above and below 7.0 per-
forming a Kaplan–Meyer estimate of the corresponding
survivor functions and a log-rank test to assess the statisti-
cally significant difference between the estimated survival
functions (log-rank χ2 = 11.94, P = 0.0005). Statistical ana-
lysis was performed using the statistical software STATA,
version 14.
Results
Clinical features
One hundred consecutive AOSD patients (66 men, 34
women), whose age at diagnosis was 45.35 ± 16.23
(mean ± SD), were enrolled (Table 1). Table 2 com-
pares the clinical and laboratory features of patients
assessed at admission. Briefly, all patients experienced
fever, 86 showed joint involvement, 78 presented with
a skin rash, 62 showed hepatic involvement, and 57
experienced myalgia. In addition, 79 and 57 patients
presented with splenomegaly and lymph node enlarge-
ment, respectively. A low percentage of patients experi-
enced serositis, pericarditis, pleurisy, and weight loss. The
mean systemic score resulted in 6.11 ± 2.02 (mean ± SD,
range 2–12, median 6), indicating that the majority of pa-
tients had multi-organ involvement. In Fig. 1, we report
the statistically significant differences among the groups
with different clinical outcomes.
Sixteen patients experienced different complications at
the time of diagnosis. Specifically, 13 patients were af-
fected by AOSD-related MAS at the time of diagnosis.Bone marrow analysis showed the phagocytosis of haem-
atopoietic cells by activated macrophages in all of these
patients. The clinical features of these patients are
listed in Table 3. Two patients experienced kidney fail-
ure requiring dialysis in whom an interstitial nephritis
occurred, as assessed by kidney biopsies. Finally, one
patient experienced myocarditis as an AOSD-related
complication. Our analysis showed that higher values
of the systemic score were significantly associated with
the presence of AOSD-related complications at the time
of diagnosis. On the contrary, no correlation was found
between ESR, CRP, and/or serum ferritin levels and the
presence of AOSD-related complications at the time of
diagnosis (Table 4).
In this cohort, a strong increase of inflammatory markers
(mean ± SD) was observed: serum ferritin levels were
2560.07 ± 3726.64 ng/mL, ESR was 67.28 ± 26.65 mm/hour,
and CRP was 78.35 ± 72.76.
With regards to comorbidities at baseline, 33 patients
presented at least one comorbidity. In fact, patients
were affected by systemic arterial hypertension (n = 21),
dyslipidemia (n = 10), thyroidopathies (n = 10), type 2
diabetes (n = 8), osteoporosis (n = 5), hepatic steatosis
(n = 5), atrial fibrillation (n = 2), heart failure (n = 2),
and cardiac valvular disease (n = 2). In addition, seven
patients were affected by chronic kidney disease with
mildly reduced kidney function (Glomerular Filtration
Rate = 60–89 mL/min/1.73 m2) [36]. Chronic kidney
disease was associated with type 2 diabetes (n = 3), sys-
temic arterial hypertension (n = 3), and polycystic kidney
disease (n =1).
The monocyclic pattern, polycyclic, and chronic pat-
terns were present in 29, 22, and 33 patients, respect-
ively. In patients affected by polycyclic pattern, a mean
of 2.89 ± 0.86 flares occurring after remission and requir-
ing additional therapy were observed during follow-up.
Sixteen patients died during the follow-up period. Spe-
cifically, 10 patients died of uncontrollable MAS, two of
severe kidney failure requiring dialysis, two of multiple
organ failure, and two of severe infection related to the
immunosuppressive therapy.
Treatments
All patients received steroids at different dosages, the
mean dosage of prednisone equivalent was 321.81 ±
394.52 (mean ± SD) mg. Table 2 shows the percentage of
patients treated by pulse steroid therapy. The design of
our observational study did not establish any prior
therapeutic strategy or the tapering regimen of steroids.
We followed the general rule of commencing steroid ta-
pering once the maximum desired therapeutic benefit
has been obtained, when inadequate therapeutic benefit
has been achieved following an adequate therapeutic
strategy, or when side effects, such as type 2 diabetes or
Table 2 Demographic and clinical features of the evaluated patients stratified according the different outcomes
All patients Monocyclic course Polycyclic course Chronic course AOSD-related
death
Number of patients 100 29 22 33 16
Female/Male 66/34 20/9 12/10 12/11 12/4
Age (years), mean ± SD 45.35 ± 16.23 49.31 ± 12.47 43.81 ± 15.13 40.24 ± 15.86 50.81 ± 19.97
Clinical features
Fever, n (%) 100 (100) 29 (100) 22 (100) 33 (100) 16 (100)
Weight loss, n (%) 5 (5) 1 (3.44) 2 (9.10) 0 2 (12.5)
Rash, n (%) 78 (78) 24 (82.75) 14 (48.27) 28 (84.84) 12 (75)
Joints involvement, n (%) 86 (86) 27 (93.10) 21 (95.45) 26 (78.79) 12 (75)
Sore throat, n (%) 64 (64) 10 (34.48) 13 (59.10) 25 (75.76) 16 (100)
Myalgia, n (%) 57 (57) 12 (41.37) 15 (68.19) 16 (48.49) 14 (87.5)
Lymphadenopathy, n (%) 57 (57) 11 (37.93) 16 (72.72) 15 (45.45) 15 (93.75)
Splenomegaly, n (%) 79 (79) 22 (75.86) 20 (90.91) 23 (69.70) 14 (87.5)
Hepatic involvement, n (%) 62 (62) 18 (62.07) 16 (72.72) 18 (54.54) 10 (62.5)
Pleurisy, n (%) 14 (14) 1 (3.44) 5 (22.72) 4 (12.12) 4 (25)
Lung involvement, n (%) 13(13) 2 (6.89) 3 (13.63) 1 (3.03) 7 (43.75)
Pericarditis, n (%) 15 (15) 1 (3.44) 3 (13.63) 6 (18.18) 5 (31.25)
Abdominal pain, n (%) 18 (18) 2 (6.89) 4 (18.19) 7 (21.21) 5 (31.25)
Systemic score, mean ± SD 6.11 ± 2.02 4.93 ± 1.79 6.41 ± 2.05 6.12 ± 1.66 7.81 ± 1.54
Comorbidities, n (%) 33 (33) 6 (20.68) 8 (36.36) 9 (27.28) 10 (62.5)
Laboratory markers
Leukocytosis > 15,000/mm3, n (%) 36 (36) 4 (13.79) 7 (31.82) 19 (57.57) 6 (37.5)
Serum ferritin (ng/mL), mean ± SD 2560.07 ± 3726.64 1634.82 ± 1198.92 2541.04 ± 3028.16 2886.09 ± 5438.65 3560.94 ± 3004.93
ESR (mm/hour), mean ± SD 67.28 ± 26.65 68.93 ± 23.94 61.81 ± 26.84 65.18 ± 26.77 74.93 ± 28.29
CRP (mg/L), mean ± SD 78.35 ± 72.76 83.83 ± 70.38 48.34 ± 35.64 72.16 ± 83.47 111.37 ± 61.76
Complications
MAS 13 (13) 0 3 (13.63) 0 10 (62.5)
Kidney failure 2 (2) 0 0 0 2 (12.5)
Myocarditis 1 (1) 1 (3.44) 0 0 0
Treatments
Low dosage of steroid monotherapy, n (%) 4 (4) 0 0 4 (12.12) 0
High dosage steroid monotherapy, n (%) 39 (39) 24 (79.31) 2 (9.1) 7 (21.21) 6 (93.75)
High dosage steroid pulse therapy
(500–1000 mg), n (%)
37 (37) 10 (34.48) 9 (40.91) 5 (15.15) 13 (81.25)
sDMARD(s) 55 (55) 5 (17.24) 18 (81.82) 22 (66.67) 10 (62.5)
Combination therapy, steroids + sDMARD(s), n (%) 25 (25) 5 (17.24) 8 (36.36) 10 (30.3) 2 (12.5)
Combination therapy, steroids + biologics
agent ± sDMARD(s), n (%)
32 (32) 0 12 (54.55) 12 (36.37) 8 (50)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, MAS macrophage activation, sDMARDs synthetic disease-modifying anti-rheumatic drugs
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medication [37]. Four patients were treated with low/
medium dose of steroid monotherapy, whereas 39 pa-
tients were treated by high dose steroid monotherapy.
Fifty-five patients were treated with a combination ther-
apy, including sDMARD(s) and steroids: patients received
MTX (n = 43), cyclosporine A (n = 8), hydroxychloroquine(n = 4), cyclophosphamide (n = 2), a combination therapy
with MTX and cyclosporine A (n = 5), and MTX and
hydroxychloroquine (n = 2). Thirty-two patients were
treated with a combination therapy including biologic
agents and/or sDMARD and/or steroids: patients received
TNF inhibitors (n = 18), tocilizumab (n = 8), and anakinra
(n = 6). Among patients treated with biologic agents, 29
Fig. 1 Clinical and laboratory differences among the groups with different clinical outcomes. a Panel shows the values of the systemic score, at
the time of diagnosis, among the different groups according the clinical outcome, the highest values are observed in the AOSD-related death
group. b and c Panels show the serum levels of C-reactive protein and ferritin, at the time of diagnosis; these levels are statistically higher in
AOSD-related death group when compared with the other groups. Values are expressed as mean ± SD (*P < 0.05; **P < 0.001; ***P < 0.0001).
Table 3 Demographic and clinical features of the enrolled
patients with macrophage activation syndrome (MAS)
Clinical features
Number of patients 13
Women/men 7/6
Age (years), mean ± SD 52.02 ± 19.01
Triggering factor
AOSD flare, number (%) 13 (100)
Lymphoma, number (%) 0
Infectious disease, number (%) 0
Laboratory features
WBC (103/mL), mean ± SD 3.28 ± 1.36
RBC (103/mL), mean ± SD 3.31 ± 0.69
HB (gr/dL), mean ± SD 9.19 ± 2.05
PLT (103/mL), mean ± SD 55.52 ± 46.54
Serum Ferritin (ng/mL), mean ± SD 4362.15 ± 7569.70
ESR (mm/hour), mean ± SD 71.23 ± 30.19
CRP (mg/L), mean ± SD 74.76 ± 46.92
Triglycerides (mg/dL), mean ± SD 183.12 ± 69.33
ASAT (IU/L), mean ± SD 74.59 ± 41.89
ALAT (IU/L), mean ± SD 129.98 ± 91.21
Treatments
High dosage steroid pulses, number (%) 13 (100)
Immunosuppressive drugs, number (%) 7 (53.84)
Cyclosporine A, number (%) 5 (38.46)
Methotrexate, number (%) 2 (15.38)
Etoposide 0
Biologic drugs 2 (15.38)
Deaths, number (%) 10 (76.92)
Number of relapses in MAS-survivors patients,
mean ± SD
2.66 ± 1.69
AOSD adult-onset Still’s disease, IU international unit, WBC white blood cell
count, RBC red blood cells, HB hemoglobin, PLT platelet count, ESR erythrocyte
sedimentation rate, CRP C-reactive protein, ASAT aspartate aminotransferase,
ALAT alanine aminotransferase
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agent and sDMARD and steroids, and three were treated
with a combination therapy biologic agent and steroids.
Twenty-one out of 32 patients treated with biologic agents
received high dose steroids. The above results are summa-
rized in Table 5.
Regression analyses among clinical features at the time of
diagnosis and outcomes
An ordinal regression analysis was performed to estimate
whether sex, systemic score, the presence of AOSD-related
complications, the presence of comorbidities, serum ferritin
levels, and inflammatory markers, at the time of diagnosis,
were associated with outcome of our patients (Table 6).
Due to the low number of AOSD-related complications
at the time of diagnosis we decided to aggregate these
covariates into a single dichotomous variable in order
to minimize the possible confounding effect of the low
number of patients on the statistical analyses. In addition,
the aggregation of these covariates might improve the
generalization of the results and thus their clinical
usability.
Our results showed that the higher values of the sys-
temic score, the presence of AOSD-related complication,
and the presence of comorbidities were associated with
the outcome. The results suggest that higher values of the
systemic score or the presence of comorbidities at the
time of diagnosis were predictive of a more severe out-
come than the monocyclic form (Table 7). Furthermore,Table 4 Correlation between AOSD-related complications and
selected clinical variables
Clinical variables Coefficient, P value
Systemic score 0.40, < 0.001*
Serum ferritin 0.13, 0.20
Erythrocyte sedimentation rate 0.06, 0.56
C-reactive protein 0.18, 0.07
*Statistically significant
Table 5 Treatments of enrolled Adult-onset Still’s disease patients
at the time of diagnosis
Treatment Patients
Steroids, number (%) 100 (100)
Low dose of steroids monotherapy, number (%) 4 (4)
High dose of steroids monotherapy, number (%) 39 (39)
Steroid pulse therapy, number (%) 37 (37)
sDMARD, number (%) 55 (55)
Methotrexate 43 (43)
Cyclosporine A 8 (8)
Hydroxychloroquine 4 (4)
Cyclophosphamide 2 (2)
Methotrexate and cyclosporine A 5 (5)
Methotrexate and hydroxychloroquine 2 (2)
Biologic agents, number (%) 32 (32)
Infliximab 10 (10)
Tocilizumab 8 (8)
Etanercept 7 (7)
Anakinra 6 (6)
Certolizumab pegol 1 (1)
Combination therapy, steroids + sDMARD(s), number (%) 25 (25)
Combination therapy, steroids + biologics agent ±
sDMARD(s), number (%)
32 (32)
sDMARDs synthetic disease-modifying anti-rheumatic drugs
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AOSD-related complications at the time of diagnosis were
significantly associated with mortality in our cohort, our
study showed that AOSD-related complications are the
main clinical features negatively influencing the survival of
AOSD patients.
Validation of the systemic score
In our cohort, we observed that higher levels of the sys-
temic score were predictive of a more severe outcome
than the monocyclic form. On this basis, we supposed
that a reasonable clinical application of the systemic score,Table 6 Ordinal regression analysis between clinical features at the
Odds ratio Stan
Gender 1.40
Systemic score 1.42
AOSD-related complication 51.57
Comorbidities 3.89
Serum Ferritin 1.00
Erythrocyte sedimentation rate 0.99
C-reactive protein 0.99
Time of observation 0.92
AOSD Adult-onset Still’s disease
*Statistically significantas predictor of the disease condition, might be proposed.
Thus, a specific statistical analysis was performed in order
to validate this score.
A statistical association between AOSD-related death
and the systemic score was preliminarily assessed (χ2
(df = 10) = 23.32; P = 0.01). Then, a ROC analysis valid-
ation was performed, leading to an overall performance
of the test in terms of the area under the ROC curve
(AUC = 0.80 ± 0.06, 95% CI, 0.68–0.91). The test sensi-
tivity and specificity was estimated according to the
Youden criteria, obtaining a systemic score cut-off of
7.0 (systemic score ≥ 7.0; sensitivity: 75.00%; specificity:
67.86%). The last step was to test the consistency of this
cut-off in discriminating the survival between patients
having the systemic score upper and lower of 7.0, per-
forming a Kaplan–Meyer estimate of the corresponding
survivor functions and a log-rank test to assess the sta-
tistically significant difference between the survival
functions estimated (log-rank χ2 = 11.94, P = 0.0005).
Finally, Kaplan–Meier analysis showed a significant as-
sociation between the systemic score ≥ 7.0 and mortality
(P = 0.0005). The prognostic impact of systemic score ≥ 7.0
is shown in Fig. 2.
Discussion
AOSD is a rare systemic inflammatory disorder, charac-
terized by a higher mortality rate. Despite increasing
progress in unraveling the pathogenesis of the disease,
evidence-based data are still lacking and, consequently,
the disease course is unpredictable at onset and the
therapeutic approach is still largely anecdotal [2, 10, 11, 14].
To our knowledge, our study is the first observational study
in a large cohort of AOSD patients to investigate the
prognostic factors present at the time of diagnosis that
may be associated with different outcomes and the
prognostic impact of systemic score ≥ 7.0.
As far as the clinical picture is concerned, all our pa-
tients experienced fever, frequently associated with both
joint and skin involvement, mirroring data previously
published [5, 6, 8, 27, 38–41]. In fact, it has been reportedtime of diagnosis and outcomes
dard error P 95% confidence interval
0.66 0.48 0.55–3.54
0.17 0.011* 1.12–1.81
40.61 <0.0001* 11.02–241.36
1.94 0.021* 1.46–10.35
0.00 0.57 1.00–1.00
0.01 0.54 0.98–1.01
0.00 0.07 0.99–1.00
0.08 0.37 0.78–1.10
Table 7 Regression analyses among clinical features at the time of diagnosis and different outcomes
Odds ratio Standard error P 95% confidence interval
Monocyclic pattern
Systemic score 0.60 0.13 0.019* 0.39–0.92
AOSD-related complication 0.32 0.38 0.34 0.03–3.34
Comorbidities 0.13 0.11 0.017* 0.02–0.69
Polycyclic pattern
Systemic score 1.13 0.14 0.31 0.89–1.46
AOSD-related complication 1
Comorbidities 2.82 1.52 0.049* 0.98–8.16
Chronic pattern
Systemic score 1.01 0.15 0.90 0.76–1.36
AOSD-related complication 1.84 1.35 0.40 0.43–7.81
Comorbidities 1.12 0.66 0.84 0.35–3.61
AOSD-related death
Systemic score 1.49 0.30 0.04* 1.00–2.23
AOSD-related complication 33.52 34.63 0.001* 4.22–253.92
Comorbidities 1.38 1.35 0.34 0.20–9.36
AOSD Adult-onset Still’s disease
*Statistically significant
Ruscitti et al. BMC Medicine  (2016) 14:194 Page 8 of 11that fever occurs in 60–100% of AOSD patients, typically
with the highest temperatures occurring in the evening.
Fever usually precedes the onset of other manifestations
[2, 3]. Joint involvement is reported in 70–100% of these
patients, mainly in wrists, knees, and ankles. At the onset
of disease, arthritis may be mild and transient, sometimes
evolving into a chronic destructive symmetrical polyarthri-
tis with carpal ankylosis [5, 6, 8]. Further, 60–80% of
AOSD patients experience a macular or maculopapular
evanescent salmon-pink skin rash associated with the
fever spiking [38–41]; some patients, those with a usuallyFig. 2 Kaplan–Meier estimates of survival according to systemic score. a Th
was performed with an overall performance of the test in terms of the area
sensitivity and specificity were estimated according the Youden criteria, ob
67.86%). b The panel shows the prognostic impact of systemic score≥ 7.0.
systemic score≥ 7.0 and mortality (P = 0.0005)more severe outcome, may experience this skin involve-
ment for many weeks [7, 42]. Similar to previous studies
[22, 24], a strong increase of inflammatory markers as well
as of serum ferritin levels were observed herein [43, 44],
confirming the systemic nature of the disease. Although it
has been proposed that AOSD might be included within
the so called “Hyperferritinemic Syndrome”, a common
umbrella gathering different diseases in which the in-
creased circulating ferritin levels might not only reflect
an acute phase response but be directly involved in in-
flammation [25], our study did not find any correlatione panel shows the ROC analysis validation for the systemic score. It
under the ROC curve (AUC = 0.80 ± 0.06, 95% CI, 0.68–0.91). The
taining a systemic score cut-off of 7.0 (sensitivity: 75.00%; specificity:
The Kaplan–Meier analysis showed a significant association between a
Ruscitti et al. BMC Medicine  (2016) 14:194 Page 9 of 11between the levels of this molecule and the patient
outcomes.
With regards to the complications, it must be noted
that 13 patients simultaneously fulfilled the diagnostic
criteria for AOSD and MAS, a life-threatening complica-
tion of several diseases, including AOSD, at the time of
diagnosis [15–17]. Our results confirmed previous pa-
pers in which up to 16% of AOSD patients experienced
this complication [5, 6, 14]. Interestingly, the clinical fea-
tures of these MAS patients mirrored those reported in
available literature [15, 16, 34]. Our patients showed
peripheral cytopenias associated with high levels of
both inflammatory markers and serum ferritin. All
these patients were treated with a steroid pulse therapy
[43, 45, 46]. Of note, it has been proposed that AOSD
and MAS may be part of the same disease spectrum, in
which AOSD should be considered the milder form [14],
and the occurrence of MAS might be misdiagnosed due to
the immunosuppressive treatments used to control an
AOSD flare [14, 15]. AOSD may be associated with
life-threatening manifestations, such as myocarditis,
adult respiratory distress syndrome, and pulmonary
hypertension [14]. Although the prognosis of AOSD is
generally favorable, death may occur in some patients
due to these complications, and early recognition and
management of these conditions is associated with de-
creased mortality in these patients [14]. In addition, our
analysis showed that the higher values of the systemic
score, a score evaluating the multi-visceral involvement,
were associated with the presence of AOSD-related
complications.
A favorable outcome was showed in the majority of
patients: 29% out of the enrolled patients experienced
the monocyclic pattern and maintained remission during
follow-up, 55% developed a chronic form with a polycyc-
lic (22%) or chronic pattern (33%).
In our study, we focused on the prognostic tools at the
time of diagnosis and this validated severity score may
be applied to all the AOSD patients, identifying, at the
time of diagnosis, those patients with the likelihood of a
more severe outcome. In fact, our study confirms that a
cut-off at 7.0 of the systemic score at the time of diagnosis
identifies those patients at higher risk of AOSD-related
death. Our results suggest that multi-organ involvement
at the time of diagnosis is predictive of a more severe out-
come and increased mortality.
Furthermore, our study suggests that not only multi-
organ involvement but also the presence of comorbidities
at the time of diagnosis may be predictive of the more
severe outcomes. In fact, it is well-known from epidemio-
logical studies that patients with comorbid illnesses, inde-
pendently from the primary disease, may be at higher risk
of complications or death, less able to tolerate specific pro-
cedures, and less responsive to therapy, when compared topatients with the same primary disease but without these
conditions [29, 47].
In our cohort, we observed 16 AOSD-related deaths;
uncontrollable MAS was the most frequent complication
associated with death. Our study suggests that higher
values of the systemic score and the presence of AOSD-
related complications at the time of diagnosis were signifi-
cantly associated with mortality, negatively influencing
survival. The higher mortality rate observed herein does
not confirm results from other European series in which a
lower mortality rate was reported [27, 40], but mirrors re-
cently published data observed in Asiatic populations
reporting a similar mortality rate as well as the main
causes of death [48, 49].
When we analyzed the AOSD treatments at the time
of diagnosis, we observed that the majority of patients
were treated with combination therapy including ste-
roids and MTX, the latter showing both steroid-sparing
effect and effectiveness [38–40, 50, 51]. In fact, it is well-
known that both steroids and MTX present strong anti-
inflammatory and immunosuppressive effects [52–54].
Recently, multiple lines of evidence reported the efficacy
of biologic agents in controlling AOSD clinical symptoms
in steroids- and sDMARD-refractory AOSD [55–57]. In
our cohort, according with the suggestions of Jamilloux
et al. [58], patients resistant to “traditional” therapies were
treated with TNF-inhibitors or with IL-1 or IL-6 antago-
nists. We did not analyze any possible association between
the use of biological treatments, as well as the other thera-
peutic schemes, and the different outcomes. Our study
was not specifically designed to analyze the effect of differ-
ent drugs on the outcome. Furthermore, this may result in
a “confounding by indication” bias, i.e., patients treated
with biologics were the most severe ones [59, 60]. Thus,
lacking international guidelines for AOSD treatment, it is
probable that clinicians decided to prescribe a more inten-
sive treatment to the patients that, in their opinion, were
affected by a more aggressive disease [59, 60]. Confound-
ing by indication is a potential limitation in the follow-up
of observational studies to evaluate the possible effects of
different therapeutic strategies, thus strongly limiting the
interpretation of the results [59–61]. In addition, it must
be noted that this kind of study generally may display
some further limitations; in fact, although we performed a
retrospective analysis of patients prospectively admitted to
three different rheumatologic centers, some confounding
factors, such as misclassification or information biases,
might be present in any retrospective series.
Conclusions
In conclusion, our study showed that a higher systemic
score and/or the presence of AOSD-related complications
at the time of diagnosis were significantly associated with
a poor, unfavorable outcome. Of note, this works is the
Ruscitti et al. BMC Medicine  (2016) 14:194 Page 10 of 11first demonstration that a systemic score cut-off of 7.0 has
a strong prognostic impact, identifying patients at risk of
AOSD-related death. The results of our study, identifying
the prognostic factors which may be detectable at the time
of diagnosis and validating a severity score for the disease,
may be helpful for the clinical management of AOSD pa-
tients in the future.
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